目的:观察分化型甲状腺癌患者131I治疗后6个月肝肾功能及白细胞变化.方法:分析分化型甲状腺癌患者131I治疗前及治疗后6个月的肝肾功能及白细胞计数的资料变化.肝功能以ALT、AST水平进行评价,两者均正常则认为肝功能正常,两者任一异常认为肝功能受损,将治疗前后进行配对两组二分类资料McNemar检验.肾功能取血尿素氮、血肌酐水平,进行配对两组二分类资料McNemar检验.结果:40例患者行72次131I治疗,平均累计接受(7.86±5.67)GBq剂量.治疗前后6个月,患者治疗1次或多次白细胞计数比较差异无统计学意义;肝功能出现受损的几率无统计学差异,ALT及AST均无明显差异;所有患者治疗前肾功能均正常,经过单次或多次治疗均无一例肾功能异常.结论:甲状腺癌患者大剂量131I治疗后6个月未发现骨髓抑制及肝肾功能不良.%Objective:To observe the hepatic and renal function, WBC count changes of thyroid cancer patients six months after 131I therapy. Methods: 131I therapies on 40 patients were analyzed, hepatic and renal function,blood regular test were measured before and six month after therapy. Results: Only ALT/AST of hepatic function was observed abnormal in all of 144 tests. All ALT/AST were normal. All renal function tests were normal in all of 144 tests. Pared t tests of WBC counts revealed no significant difference before and after I therapy. Conclusion: High dose of I was needed in treating thyroid cancer, and I was absorbed by remnant thyroid after six month treatment no evidence proves hepatic, renal function defect, or myelosuppression.
展开▼
